Abstracts tagged "microbiome"

Abstract Number: LB15 • ACR Convergence 2025
Dietary Fiber Supplementation Enhances Methotrexate Response and Restores Th17/Treg Balance in Rheumatoid Arthritis: Results from the Superfibre Randomized Trial
Claire Immediato Daien¹, Jean-Pierre Hellier², Zübeyir Salis³, Gaël Mouterde⁴, Jacques Morel⁵, Laurence Macia⁶ and Rachel audo⁴, ¹CHU and Univesrity of Montpellier, Montpellier, France, ²CHU Montpellier, Arles, France, ³University of Montpellier, Montpellier, France, ⁴CHU Montpellier, Montpellier, France, ⁵CHU and University of Montpellier, Montpellier, France, ⁶Sydney University, Brisbane, Australia
Background/Purpose: Gut dysbiosis and Th17/Treg imbalance contribute to rheumatoid arthritis (RA). Additionally, methotrexate (MTX) efficacy depends on gut microbiota composition, especially on the presence of B.…
Abstract Number: 1781 • ACR Convergence 2025
Specific gut microbiome remodeling occurs after induction of OA via DMM surgery compared to sham surgery
Aleksander Szymczak¹, Cindy Miranda Brawner², Nicholas Hanebutt², Gabriella Dyson², Montana Barrett², Anna Rapp³, Carla Scanzello⁴ and Matlock Jeffries¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Oklahoma City, ³University of Pennsylavnia, Philadelphia, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: The destabilization of the medial meniscus (DMM) model is widely used in murine OA research due to its reproducibility and ability to recapitulate key…
Abstract Number: 0491 • ACR Convergence 2025
Association of Short Chain Fatty Acids and Diet with Disease Activity and Methotrexate Response in New Onset Rheumatoid Arthritis: A Proof of Principle Study
Kaci French¹, Luz Alvarado², Rebecca Haberman³ and Rebecca Blank³, ¹NYU Langone, New York, NY, ²NYU Langone, New York, ³NYU Langone Health, New York, NY
Background/Purpose: Diet, the gut microbiome, and gut microbial metabolites have been implicated in rheumatoid arthritis (RA) development and modulation. Seafood based-omega-3 fatty acids modulate inflammatory…
Abstract Number: 1759 • ACR Convergence 2025
Role of a pathogenic bacterial factor produced by a human gut pathobiont in inducing platelet activation and thrombo-inflammation.
Abhimanyu Amarnani¹, Cristobal F. Rivera², Susan RS Gottesman³, Zakia Azad¹, Mingyang Yi⁴, Joshua Prasad⁴, Cynthia Loomis⁴, Andy Lee⁴, Nimat Ullah⁴, Bhama Ramkhelawon⁵ and Gregg J. Silverman¹, ¹New York University Grossman School of Medicine, New York, NY, ²New York University Grossman Department of Surgery, New York, ³SUNY Downstate Health Sciences University, New York, ⁴New York University Grossman School of Medicine, New York, ⁵New York University Department of Surgery, New York
Background/Purpose: SLE is an autoimmune disease that causes progressive multi-organ damage, leading to renal injury, or lupus nephritis (LN), in half of patients. Despite treatment,…
Abstract Number: 0482 • ACR Convergence 2025
R-2487, a Synthetic Biology-Based Oral Immunotherapy, Promotes Treg-Mediated Immune Rebalancing and Reduces Disease Activity in Rheumatoid Arthritis Patients
Christian Furlan Freguia¹, Janet Stephens¹, Sathya Janardhanan¹, Chuck Bourne¹, Kaitlyn Skeie¹, Hudson Lowe¹, David Pascual² and Gary Fanger¹, ¹Rise Therapeutics, Rockville, MD, ²University of Wyoming, Laramie, WY
Background/Purpose: R-2487 is a novel, orally delivered, synthetic biology-based immunotherapy that utilizes Lactococcus lactis as a carrier vehicle to deliver Colonization Factor Antigen I (CFA/I)…
Abstract Number: 1565 • ACR Convergence 2025
Association of the gastrointestinal (GI) microbiome and GI symptoms in systemic sclerosis: An international, multi-center, observational study
Zsuzsanna McMahan¹, Swapna Joshi², Jennifer Labus², Arissa Young², Andrea Low³, Vanessa Smith⁴, Susanna Proudman⁵, Antonia Valenzuela⁶, Phoebe Hunter⁷, Kristofer Andréasson⁸, Ezinne Aja², Jonathan Jacobs² and Elizabeth Volkmann⁹, ¹UT Health Houston, Houston, TX, ²UCLA, Los Angeles, ³Singapore General Hospital, SingHealth; Duke-NUS, Singapore, Singapore, ⁴Ghent University Hospital, Gent, Belgium, ⁵Royal Adelaide Hospital and University of Adelaide, Medindie, South Australia, Australia, ⁶Pontificia Universidad Catolica de Chile, Santiago, Chile, ⁷Royal Adelaide Hospital, Adelaide, Australia, ⁸Skåne University Hospital, Department of Rheumatology, Lund, Sweden, Lund, Sweden, ⁹Division of Rheumatology, Department of Medicine, University of California, David Geffen School of Medicine, Los Angeles, CA, USA, Los Angeles, CA
Background/Purpose: GI disease is highly prevalent in systemic sclerosis (SSc) and adversely affects quality of life and survival in SSc. The pathogenesis of GI disease…
Abstract Number: 0466 • ACR Convergence 2025
Pilot Study Demonstrates Altered Intestinal Mucosal Microbiome in Patients with Rheumatoid Arthritis versus Control Subjects
Tulsi Joishy¹, Anastasiia Phothisane², Phicharmon Kulapatana² and Michelle Ormseth¹, ¹Vanderbilt University Medical Center, Nashville, ²Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease that is thought to originate at the mucosa. Despite the mucosa’s importance, few studies have examined…
Abstract Number: 2643 • ACR Convergence 2025
Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy
Rahul Bodkhe¹, Kai Trepka¹, Diego Orellana¹, Rebecca Blank², Peter Turnbaugh³, Jose Scher⁴ and Renuka Nayak⁵, ¹University of California San Francisco, San Francisco, CA, ²NYU Langone Health, New York, NY, ³University of California, San Francisco, San Francisco, CA, ⁴New York University School of Medicine, New York, NY, ⁵University of California, San Francisco (UCSF), San Francisco, CA
Background/Purpose: Rheumatoid arthritis (RA) is a common systemic autoimmune disease that targets the joints, causing persistent pain and swelling. Oral methotrexate (MTX) remains first-line therapy…
Abstract Number: 1338 • ACR Convergence 2025
Short-Chain Fatty Acids and Their Gut Microbial Metabolic Pathways Distinguish Rheumatoid Arthritis in Discordant Monozygotic Twins
Rebecca Blank¹, Kevin Bu², Xinyuan Zhang³, Weixi Chen⁴, Ian Cunningham⁴, jeremy sokolove⁵, Lauren Lahey⁶, Adriana Heguy⁴, Rhina Medina⁴, Carles Ubeda⁷, Renuka Nayak⁸, Jiyuan Hu⁴, Adam Cantor⁹, Jakleen Lee⁹, Frances Williams¹⁰, Jose Clemente² and Jose Scher¹¹, ¹NYU Langone Health, New York, NY, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Kings College London, London, United Kingdom, ⁴NYU Grossman School of Medicine, New York, ⁵odyssey, Berwyn, PA, ⁶Stanford, Palo Alto, ⁷Fisabio, Madrid, ⁸University of California, San Francisco (UCSF), San Francisco, CA, ⁹Icahn School of Medicine, New York, ¹⁰Kings College London, London, ¹¹New York University School of Medicine, New York, NY
Background/Purpose: Although genetic factors have been identified in the pathogenesis of RA, the concordance rate in monozygotic (MZ) twins is low, suggesting that other factors…
Abstract Number: 0400 • ACR Convergence 2025
Recent Antibiotic Exposure and Response to Treatment of Juvenile Idiopathic Arthritis
Daniel Horton¹, Charu Verma², Sanika Rege², Alicia Iizuka², Matthew Iozzio³, Dawn Koffman³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard², Lauren Parlett⁶, Carlos Rose⁷ and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, ³Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, ⁴Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, ⁵New Jersey Medical School, Newark, NJ, ⁶Carelon Research, Inc, Wilmington, DE, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, New Brunswick
Background/Purpose: Juvenile idiopathic arthritis (JIA), the most common pediatric rheumatic disease, has been tied to microbiome disruption (dysbiosis). Dysbiosis in adults with arthritis affects response…
Abstract Number: 2639 • ACR Convergence 2025
Gut Microbiome Signatures Forecast Clinical Response to Methotrexate in Treatment-Naïve Early Rheumatoid Arthritis
VINOD GUPTA¹, Adam Koller¹, Benjamin Hur¹, Marissa Bailey¹, Kara Delger², Elena myasoedova¹, Vanessa Kronzer¹, John Davis¹ and Jaeyun Sung¹, ¹Mayo Clinic, ROCHESTER, MN, ²Mayo Clinic, St Charles, MN
Background/Purpose: Oral methotrexate (MTX) is the cornerstone treatment for newly diagnosed rheumatoid arthritis (RA), yet up to 50% of patients do not respond adequately. Early…
Abstract Number: 1329 • ACR Convergence 2025
Relationship Between Circulating Bacterial Small RNAs, Methotrexate Response, and Microbiome in New Onset Rheumatoid Arthritis
Carolina Ramirez-Becerra¹, Tulsi Joishy², Sheau-Chiann Chen², Marisol Ramirez-Solano², Quanhu Sheng², Peter Turnbaugh³, Carles Ubeda⁴, Renuka Nayak⁵, Rebecca Blank⁶, Jose Scher⁷ and Michelle Ormseth², ¹Vanderbilt University Medical Center, Nashville, TN, ²Vanderbilt University Medical Center, Nashville, ³University of California, San Francisco, San Francisco, CA, ⁴Fisabio, Madrid, ⁵University of California, San Francisco (UCSF), San Francisco, CA, ⁶NYU Langone Health, New York, NY, ⁷New York University School of Medicine, New York, NY
Background/Purpose: Microbiome and microbial products are possible contributors and predictors to methotrexate (MTX) response variability. Bacterial small RNAs (sRNAs) are found in human plasma and…
Abstract Number: 0322 • ACR Convergence 2025
Metabolites Reflective of the Gut Microbiome Relate to Future Incident Knee Osteoarthritis: Data from the Osteoarthritis Initiative
Jeffrey Driban¹, Shike Xu², Timothy McAlington³, John Haran⁴, Julieann Patarini⁴ and Bing Lu⁵, ¹University of Massachusetts Chan Medical School, Marlborough, NH, ²University of Connecticut Health Center, Farmington, CT, ³UMass Chan School of Medicine, Arlington, MA, ⁴UMass Chan Medical School, Worcester, MA, ⁵UConn Health Center, Newton, MA
Background/Purpose: Numerous cross-sectional and animal studies have linked an altered gut microbiome to osteoarthritis (OA). Human studies are needed to explore the association between the…
Abstract Number: 2622 • ACR Convergence 2025
Oral Microbiome Dysbiosis and Oral-gut Microbial Network Disruption in Hand Osteoarthritis: Data from the Xiangya Osteoarthritis Study
Jiatian Li¹, Yadan Xiao², Tuo Yang¹, david Hunter³, Weiya Zhang⁴, Michael Doherty⁴, Yuqing Zhang⁵, Zidan Yang¹, Yilun Wang¹, Dongxing Xie¹, Changjun Li¹, Wei Li¹, Zeqin Wen¹, Chao Zeng¹, Guanghua Lei¹ and Jie Wei¹, ¹Xiangya Hospital, Central South University, Changsha, Hunan, China (People's Republic), ²Xiangya School of Public Health, Central South University, Changsha, Hunan, China (People's Republic), ³Sydney Musculoskeletal Health, University of Sydney, St Leonards, New South Wales, Australia, ⁴School of Medicine, University of Nottingham, Nottingham, United Kingdom, ⁵Massachusetts General Hospital, Quincy, MA
Background/Purpose: The oral microbiome plays a critical role in modulating systemic inflammation and maintaining immune homeostasis, partly through its interactions with the gut microbiome. Although…
Abstract Number: 1119 • ACR Convergence 2025
Microbial activation of cytotoxic CD8⁺ T cells promotes skin immune-related adverse events in patients treated with immune checkpoint inhibitors
Shady Younis¹, Suman Acharya¹, Gayathri Swaminathan¹, Heidi Wong¹, Hannah Kim¹, Alec Eschholz¹, Subramanya Hegde², Andrew McKnight³, William Robinson⁴ and Lisa Zaba¹, ¹Stanford University, Stanford, CA, ²Sanofi US, New Jersey, MA, ³Sanofi US, Cambridge, MA, ⁴Stanford University, Palo Alto, CA
Background/Purpose: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their use is often limited by immune-related adverse events (irAEs), particularly in barrier tissues such…

1
2
3
…
13
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].